Adimmune Corp
TWSE:4142
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| TW |
|
Adimmune Corp
TWSE:4142
|
8B TWD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
398.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.3B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
177.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.7B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.5B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -22 082.4% |
| 30th Percentile | 1% |
| Median | 5.3% |
| 70th Percentile | 11.1% |
| Max | 1 580% |
Other Profitability Ratios
Adimmune Corp
Glance View
ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Adimmune Corp is -42.3%, which is below its 3-year median of -18.4%.
Over the last 3 years, Adimmune Corp’s Net Margin has decreased from 21.3% to -42.3%. During this period, it reached a low of -42.3% on Sep 30, 2025 and a high of 21.3% on Aug 30, 2022.
